HagopM.KantarjianMDFASCO

PubMed

• Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia.
  Elias Jabbour, Fadi G Haddad, Koji Sasaki, Bing Z Carter, Yesid Alvarado, Cedric Nasnas, Lewis Nasr, Lucia Masarova, Naval Daver, Naveen Pemmaraju, Nicholas J Short, J...> ;Cancer. 2024 Apr 9
• Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study.
  Prithviraj Bose, Lucia Masarova, Naveen Pemmaraju, Sharon D Bledsoe, Naval G Daver, Elias J Jabbour, Tapan M Kadia, Zeev Estrov, Steven M Kornblau, Michael Andreeff, N...> ;Haematologica. 2024 Apr 4
• Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia.
  Elias Jabbour, Gerhard Zugmaier, Vaibhav Agrawal, Pilar Martínez-Sánchez, José J Rifón Roca, Ryan D Cassaday, Boris Böll, Anita Rijneveld, Maher Abdul-Hay, Françoise H...> ;American Journal of Hematology. 2024 Apr 1
• Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups.
  Alex Bataller, Courtney D DiNardo, Alexandre Bazinet, Naval G Daver, Abhishek Maiti, Gautam Borthakur, Nicholas Short, Koji Sasaki, Elias J Jabbour, Ghayas C Issa, Nav...> ;American Journal of Hematology. 2024 Apr 1
• Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm,...
  Alexandre Bazinet, Hagop Kantarjian, Alex Bataller, Naveen Pemmaraju, Gautam Borthakur, Kelly Chien, Yesid Alvarado, Prithviraj Bose, Elias Jabbour, Musa Yilmaz, Court...> ;The Lancet. Haematology. 2024 Apr 1
• Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL.
  Yaqi Zhao, Nicholas J Short, Hagop M Kantarjian, Ti-Cheng Chang, Pankaj S Ghate Ph.D, Chunxu Qu, Walid Macaron, Nitin Jain, Beenu Thakral, Aaron Phillips, Joseph D Kho...> ;Blood. 2024 Mar 29
• The presence of additional cytogenetic abnormalities (ACAs) or Philadelphia chromosome variants do not adversely affect the achievement of treatment-free remission in ...
  Fadi G Haddad, Koji Sasaki, Ghayas C Issa, Elias Jabbour, Hagop Kantarjian> ;American Journal of Hematology. 2024 Mar 28
• Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm.
  Alex Bataller, Georgina Gener-Ricos, Emmanuel Almanza, Kelly Sharon Chien, Samuel Urrutia, Alexandre Bazinet, Juan Jose Rodriguez-Sevilla, Danielle Hammond, Koji Sasak...> ;Blood Advances. 2024 Mar 21
• SOHO State of the Art Updates and Next Questions | Novel Agents and the Diminishing Role of Allogeneic Stem Cell Transplant in B-Acute Lymphoblastic Leukemia.
  Wei-Ying Jen, Elias Jabbour, Hagop M Kantarjian, Nicholas J Short> ;Clinical Lymphoma, Myeloma & Leukemia. 2024 Mar 6
• Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study.
  Alexandre Bazinet, Guillermo Garcia-Manero, Nicholas Short, Yesid Alvarado, Alex Bataller, Tareq Abuasab, Rabiul Islam, Kathryn Montalbano, Ghayas Issa, Abhishek Maiti...> ;The Lancet. Haematology. 2024 Apr 1
• Cancer patients with clonal hematopoiesis die from primary malignancy or comorbidities despite higher rates of transformation to myeloid neoplasms.
  Ziyi Li, Rashmi Kanagal-Shamanna, Guillermo Montalban-Bravo, Danielle Hammond, Sherry A Pierce, Kelly S Chien, Faustine Ong, Kunhwa Kim, Courtney D DiNardo, Koichi Tak...> ;Cancer Medicine. 2024 Mar 1
• 1 citations
  Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study.
  Naval G Daver, Pau Montesinos, Daniel J DeAngelo, Eunice S Wang, Nikolaos Papadantonakis, Elisabetta Todisco, Kendra L Sweet, Naveen Pemmaraju, Andrew A Lane, Laura To...> ;The Lancet. Oncology. 2024 Mar 1
• Using Proton Pump Inhibitors is not Associated With Adverse Outcomes in Patients With Chronic Myeloid Leukemia Treated With Dasatinib.
  Cedric Nasnas, Shilpa Paul, Caitlin Rausch, Fadi G Haddad, Koji Sasaki, Ghayas C Issa, Elias Jabbour, Hagop Kantarjian> ;Clinical Lymphoma, Myeloma & Leukemia. 2024 Feb 29
• Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia.
  Guillermo Montalban-Bravo, Juan Jose Rodriguez-Sevilla, David Michael Swanson, Rashmi Kanagal-Shamanna, Danielle Hammond, Kelly Chien, Koji Sasaki, Elias Jabbour, Cour...> ;Leukemia. 2024 Feb 28
• A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia.
  Short, N., Jabbour, E., Jain, N., Senapati, J., Nasr, L., Haddad, F., Li, Z., Hsiao, Y., Yang, J., Pemmaraju, N., Ohanian, M., Wierda, W., Montalban-Bravo, G., Borthak...> ;Blood Advances. 2024 Feb 27
• Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single-center pha...
  Issa F Khouri, Kamal Alzahrani, Hagop Kantarjian, Denái R Milton, Alison M Gulbis, Koji Sasaki, Nitin Jain, Nicholas J Short, Tapan Kadia, May Daher, Hind Rafei, Jin S...> ;American Journal of Hematology. 2024 May 1
• SOHO State of the Art Updates and Next Questions, Measurable Residual Disease in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
  Nicholas J Short, Elias Jabbour, Hagop Kantarjian> ;Clinical Lymphoma, Myeloma & Leukemia. 2024 Feb 21
• Ivosidenib significantly reduces triazole levels in patients with acute myeloid leukemia and myelodysplastic syndrome.
  Dinh, A., Savoy, J., Rausch, C., Kontoyiannis, D., Takahashi, K., Issa, G., Kantarjian, H., DiNardo, C.> ;Cancer. 2024 Feb 10
• Outcome of Patients With Relapsed Acute Promyelocytic Leukemia.
  Ravandi, F., Pierce, S., Sasaki, K., Kadia, T., DiNardo, C., Yilmaz, M., Short, N., Jabbour, E., Patel, K., Loghavi, S., Borthakur, G., Kantarjian, H.> ;Clinical Lymphoma, Myeloma & Leukemia. 2024 Feb 3
• 1 citations
  Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2...
  Bataller, A., Montalban-Bravo, G., Bazinet, A., Alvarado, Y., Chien, K., Venugopal, S., Ishizawa, J., Hammond, D., Swaminathan, M., Sasaki, K., Issa, G., Short, N., Ma...> ;The Lancet. Haematology. 2024 Mar 1
• Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase Inhibitors.
  Haddad, F., Kantarjian, H.> ;Journal of the National Comprehensive Cancer Network. 2024 Feb 1
• Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax.
  Alexandre Bazinet, Sai Prasad Desikan, Ziyi Li, Juan Jose Rodriguez-Sevilla, Sangeetha Venugopal, Samuel Urrutia, Guillermo Montalban-Bravo, Koji Sasaki, Kelly S Chien...> ;Clinical Cancer Research. 2024 Apr 1
• 2 citations
  Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission.
  Fadi G Haddad, Nicholas J Short, Jayastu Senapati, Nitin Jain, Koji Sasaki, Yesid Alvarado, Xuemei Wang, Lucia Masarova, Farhad Ravandi, Elias Jabbour, Jeffrey Jorgens...> ;Blood. 2024 Feb 1
• 1 citations
  Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials.
  Elias Jabbour, Jane Apperley, Jorge Cortes, Delphine Rea, Michael Deininger, Elisabetta Abruzzese, Charles Chuah, Daniel J DeAngelo, Andreas Hochhaus, Jeffrey H Lipton...> ;Leukemia. 2024 Mar 1
• Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory-Mutated AML.
  Short, N., Daver, N., Dinardo, C., Kadia, T., Nasr, L., Macaron, W., Yilmaz, M., Borthakur, G., Montalban-Bravo, G., Garcia-Manero, G., Issa, G., Chien, K., Jabbour, E...> ;Journal of Clinical Oncology. 2024 Jan 26
• Join now to see all

Journal Articles

• Characteristics of Patients with Myeloproliferative Neoplasms with Lymphoma, with or Without JAK Inhibitor Therapy  
  Naveen Pemmaraju, Hagop Kantarjian, Loretta Nastoupil, Srdan Verstovsek, Blood
• Venetoclax Combined with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia  
  Brian A Jonas, Courtney D DiNardo, Olga Frankfurt, Daniel A Pollyea, Keith Pratz, Anthony Letai, Martha Arellano, Marina Konopleva, Hagop M Kantarjian, Blood
• CD123 Expression Patterns and Selective Targeting with a CD123-Specific Antibody-Drug Conjugate (IMGN632) in Acute Lymphoblastic Leukemia  
  L Jeffrey Medeiros, Hagop M Kantarjian, Jeffrey L Jorgensen, Marina Konopleva, Elias J Jabbour, Joseph D Khoury, Sa A Wang, Sergej N Konoplev, Haematologica
• Mutational Landscape of myelodysplastic/myeloproliferative Neoplasm – Unclassifiable (MDS/MPN-U)  
  Aziz Nazha, Rami S Komrokji, Andrew Sochacki, Mikkael A Sekeres, Prithviraj Bose, Courtney D DiNardo, Hagop M Kantarjian, Srdan Verstovsek, Sanam Loghavi, Jaroslaw P M..., Blood
• Integrative Genomic Analysis of Adult Mixed Phenotype Acute Leukemia Delineates Lineage Associated Molecular Subtypes  
  Koichi Takahashi, Marina Konopleva, Steven Kornblau, Hagop Kantarjian, Nitin Jain, Elias Jabbour, Courtney D DiNardo, Michael Andreeff, Nature
• Integrative Genomic Analysis of Adult Mixed Phenotype Acute Leukemia Delineates Lineage Associated Molecular Subtypes  
  Koichi Takahashi, Nitin Jain, Courtney D. DiNardo, Steven Kornblau, Carlos Bueso-Ramos, Marina Konopleva, Hagop Kantarjian, Nature
• Response Kinetics and Factors Predicting Survival in Core-Binding Factor Leukemia  
  Hagop Kantarjian, Gautam Borthakur, Tapan Kadia, Nature
• Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML  
  Daniel A Pollyea, Amir T Fathi, Geoffrey L Uy, Robert K Stuart, Mikkael A Sekeres, Courtney D DiNardo, Alice S Mims, Eyal C Attar, Richard M Stone, Hagop M Kantarjian,..., The New England Journal of Medicine
• Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML  
  Hagop Kantarjian, MD, The New England Journal of Medicine
• Phase 2b Study of Two Dosing Regimens of Quizartinib Monotherapy in FLT3-ITD Mutated, Relapsed or Refractory AML  
  Alexander E Perl, Mark J Levis, Stuart L Goldberg, Martin S Tallman, Hagop M Kantarjian, Gary J Schiller, Blood
• Genomic Analyses Identify Recurrent MEF2D Fusions in Acute Lymphoblastic Leukaemia  
  Michael Borowitz, Hagop M Kantarjian, Cheryl L Willman, Stephen P Hunger, Selina M Luger, Clara D Bloomfield, Brent Wood, Jerald P Radich, Marina Konopleva, Stephen J ..., Nature
• Perspective on Costly Therapies for Hematologic Malignancies Provide "Reasonable Value"  
  Kantarjian H, HemOnctoday, 1/1/2015
• Expectation of Drug Shortages has Beome "New Norm" for Cancer Care Point/Counter Would Adoption of European Drug Pricing Practices Resolve the Issue of Drug Shortages ...  
  Kantarjian H, HemOnc today, 1/1/2015
• Leukemia Researcher Hagop Kantarjian's New Grassroots Effort Against High Cancer Drug Costs  
  Butcher L, Oncology Times, 1/1/2015
• Improving Outcomes for Patients with Acute Myeloid Leukemia in First Relapse: A Single Center Experience  
  Pemmaraju N, Kantarjian H, Garcia-Manero G, Pierce S, Cardenas-Turanzas M, Cortes J, Ravandi F, Am J Hematol, 1/1/2015
• Post Hoc Analysis of the Relationship Between Baseline White Blood Cel Count and Survival Outcome in a Randomized Phase III Trial of Decitabine in Older Patients with ...  
  Arthur C, Cermak J, Delaunay J, Mayer J, Mazur G, Thomas X, Wierzbowska A, Jones M, Berrak E, Kantarjian H, Journal of Blood Medicine, 1/1/2015
• Characteristics and Outcomes of Patients With Multiple Myeloma Who Develop Therapy-Related Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid ...  
  Pemmaraju N, Shah D, Kantarjian H, Orlowski RZ, Nogueras González GM, Baladandayuthapani V, Jain N, Wagner V, Garcia-Manero G, Shah J, Ravandi F, Pierce S, Takahashi K..., Clin Lymphoma Myeloma Leuk, 1/1/2015
• Resistance Prediction in AML: Analysis of 4,601 Patients from MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center  
  Walter RB, Othus M, Burnett AK, Lowenberg B, Kantarjian HM, Ossenkoppele GJ, Hills RK, Ravandi F, Pabst T, Evans A, Pierce SR, Vekemans MC, Appelbaum FR, Estey EH, Leukemia, 1/1/2015
• The Effect of Decitabine Dose Modification and Myelosuppression on Response and Survival in Patients With Myelodysplastic Syndromes  
  Jabbour E, Garcia-Manero G, Cornelison AM, Cortes JE, Ravandi F, Daver N, Kadia T, Teng A, Kantarjian H, Leuk Lymphoma, 1/1/2015
• A Phase I/II Study of the Janus Kinase (JAK) 1 and 2 Inhibitor Ruxolitinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia  
  Pemmaraju N, Kantarjian H, Kadia T, Cortes J, Borthakur G, Newberry K, Garcia-Manero G, Ravandi F, Jabbour E, Dellasala S, Pierce S, Verstovsek S, Clin Lymphoma Myeloma Leuk, 1/1/2015
• Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis  
  Daver N, Kantarjian H, Marcucci G, Pierce S, Brandt M, Dinardo C, Pemmaraju N, Garcia-Manero G, O'Brien S, Ferrajoli A, Verstovsek S, Popat U, Hosing C, Anderlini P, B..., Br J Haematol, 1/1/2015
• Phase I Study of a Bispecific Ligand-Directed Toxin Targeting CD22 and CD19 (DT2219) for Refractory B-cell Malignancies  
  Bachanova V, Frankel AE, Cao Q, Lewis D, Grzywacz B, Verneris MR, Ustun C, Lazaryan A, McClune B, Warlick ED, Kantarjian H, Weisdorf DJ, Miller JS, Vallera DA, Clin Cancer Res, 1/1/2015
• Myelopathy Following Intrathecal Chemotherapy in Adults: A Single Institution Experience  
  Cachia D, Kamiya-Matsuoka C, Pinnix CC, Chi L, Kantarjian HM, Cortes JE, Daver N, Woodman K, J Neurooncol, 1/1/2015
• Phase I/II Trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome  
  Strati P, Kantarjian H, Ravandi F, Nazha A, Borthakur G, Daver N, Kadia T, Estrov Z, Garcia-Manero G, Konopleva M, Rajkhowa T, Durand M, Andreeff M, Levis M, Cortes J, Am J Hematol, 1/1/2015
• Final report of a phase II study of imatinib mesylate with hyper-CVAD for the frontline treatment of adult patients with Philadelphia chromosome positive (Ph+) acute l...  
  Daver N, Thomas D, Ravandi F, Cortes J, Garris R, Jabbour E, Garcia-Manero G, Borthakur G, Kadia T, Rytting M, Konopleva M, Kantarjian H, O'Brien S, Haematologica, 1/1/2015
• Join now to see all

Books/Book Chapters

• Harrison's Principles of Internal Medicine 
  Chapter: Chronic Myeloid Leukemia 
  Page 687 - 695Kantarjian H, Cortes JEditors: Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo DL, Loscalzo J.McGraw Hill, Chicago, IL2015
• The Molecular Basis of Cancer 
  Chapter: Biology of Adult Myelocytic Leukemia and Myelodysplasia 
  Page 421 - 432Post S, Kantarjian H, Quintas-Cardama AEditors: Mendelsohn J, Gray J, Howley P, Israel M, Thompson C.Elsevier Saunders, Philadelphia, PAEdition 4th,2014
• Cancer Consult Expertise for Clinical Practice 
  Chapter: Management of B-cell acute lymphoblastic leukemia 
  Page 22 - 28Ghanem H, Kantarjian H, Jain N, Jabbour EEditors: Syed A. Abutalib, Maurie Markman.John Wiley and Sons, Inc., Hoboken, NJEdition 1st,2014
• Hematology Basic Principles and Practice 
  Chapter: Clinical Manifestations and Treatment of Acute Myeloid Leukemia 
  Page 863 - 881Faderl S, Kantarjian HEditors: R Hoffman, E Benz, L Silberstein, H Heslop, J Weitz, J Anastasi.Elsevier Saunders, Philadelphia, PAEdition 6th,2012
• Goldman's Cecil Medicine 
  Chapter: The Chronic Leukemias 
  Page 1209 - 1217Kantarjiah H, O'Brien SEditors: Goldman L, Schaffer A.Elsevier Saunders, Philadelphia, PA2012
• Hematologic Malignancies in Children, Adolescents and Young Adults 
  Chapter: Treatment of Adolescents and Young Adults with Acute Lymphoblastic Leukemia in the Modern Era 
  Nachman, J, Kantarjian, HMEditors: Cairo MS, Perkins, SL.World Scientific Publishing, Singapore2012
• Advances in Malignant Hematology 
  Chapter: Acute Lymphoblastic Leukemia 
  Page 228 - 244O'Brien S, Faderl S, Thomas D, Kantarjian HWiley-Blackwell, West Sussex, UK2011
• The MD Anderson Manual of Medical Oncology 
  Chapter: Chronic Myeloid Leukemia 
  Jabbour E. Fullmer A, Faderl S, Parikh S, Koller S, Kantarjian HEditors: Kantarjian H, Wolff R, Koller C.McGraw-Hill, ChinaEdition 2nd,2011
• Hematology / Oncology Clinics of North America: Chronic Myelogenous Leukemia 
  Chapter: Chronic Myeloid Leukemia: Mechanisms of Resistance and Treatment 
  Page 981 - 995Jabbour E, Parikh S, Kantarjian H, Cortes JEditors: DJ De Angelo, GP Canellos, N Berliner.W.B. Saunders Company, Philadelphia, PA2011
• Management of Hematologic Malignancies 
  Chapter: Chronoic Myeloid Leukemia 
  Page 68 - 80Jabbour E, Kantarjian H, Cortes JEditors: O'Brien S, Vose J, Kantarjian H.Cambridge University Press, New York, NYEdition 1st,2011
• Cancer - Principles & Practice of Oncology 
  Chapter: Myelodysplastic Syndromes 
  Page 1988 - 1996Kantarjian HEditors: DeVita V, Lawrence T, Rosenbert S.Lippincott Williams & Wilkins, Philadelphia, PAEdition 9th,2011
• Management of Hematologic Malignancies 
  Chapter: Myelodysplastic Syndromes (MDS) 
  Page 103 - 115Faderl S, Garcia-Manero G, Kantarjian HEditors: O'Brien S, Vose J, Kantarjian H.Cambridge University Press, New York, NYEdition 1st,2011
• Advances in Malignant Hematology 
  Chapter: Standard Management of Patients with Chronic Myeloid Leukemia 
  Page 71 - 86Jabbour E, Cortes J, Kantarjian HEditors: Saba H, Mufti G.Wiley-Blackwell, West Sussex UKEdition 1st,2011
• Cancer Medicine 
  Chapter: Acute Lymphoblastic Leukemia 
  Page 1591 - 1603Faderl S, Pui C, O'Brien S, Kantarjian HEditors: Hong W, Bast R, Hait W, Kufe D, Pollock R, Weichselbaum R, Holland J, Frei E.People's Medical Publishing House-USA, Shelton, CTEdition 8th,2010
• Cancer Medicine 
  Chapter: Chronic Myeloid Leukemia 
  Page 1582 - 1590Cortes J, Silver R, Kantarjian HEditors: Hong W, Bast R, Hait W, Kufe D, Pollack R, Weichselbaum R, Holland J, Frei E.People's Medical Publishing House-USA, Shelton, CTEdition 8th,2010
• Cancer Management: A Multidisciplinary Approach 
  Chapter: Chronic myeloid leukemia 
  Page 807 - 822Cortes J, Silver RT, Kantarjian HEditors: Pazdur R, Wagman L, Camphausen K, Hoskins W.The Oncology Group of CMPMedia, Norwalk, CTEdition 12th,2009
• Antifungal strategies and complications in high-risk patients 
  Chapter: Prophylactic antifungal therapy in neutropenic onco-hematology patients 
  Page 18 - 36Mattiuzzi G, Kantarjian HRemedica, London, England2009
• Abeloff's Clinical Oncology 
  Chapter: Chronic myeloid leukemia 
  Page 2279 - 2291Kantarjian H, Cortes JEditors: Abeloff M, Armitage J, Niederhuber J, Kastan M, McKenna WG.Churchill Livingstone, an imprint of Elsevier Inc, Philadelphia, PA2008
• Targeted Cancer Therapy 
  Chapter: Targeted therapy in myelodysplastic syndrome 
  Page 237 - 260Quintas-Cardama A, Kantarjian H, Garcia-Manero G, Cortes JEditors: Kurzrock R, Markman M.Humana Press, a part of Springer Science+Business Media, LLC, Totowa, NJ2008
• Chronic Myeloid Leukemia 
  Chapter: Dasatinib: A dual ABL and SRC inhibitor 
  Page 59 - 68Quintas-Cardama A, Kantarjian H, and Cortes JEditors: Cortes J and Deininger M.Informa Healthcare USA, Inc, New York, NY2007
• Nilotinib (AMN 107) for the treatment of chronic myelogenous Leukemia 
  Page 69 - 77Jabbour E, Giles F, Cortes J, O'Brien S, and Kantarjian HEditors: Cortes J and Deininger M.Informa Healthcare USA, Inc, New York, NY2007
• Cecil Medicine 
  Chapter: The Chronic Leukemias 
  Page 1397 - 1408Kantarjian H and O'Brien SEditors: Goldman L, Ausiello E.Saunders Elsevier, Philadelphia, PA2007
• MD Anderson Manual of Medical Oncology 
  Chapter: Acute Lymphoblastic Leukemia 
  Page 3 - 17Jabbour E, Borthakur G, Bueso-Ramos, C, Kantarjian H, Faderl SMcGraw Hill Professional, New York, NYEdition 1st,2006
• Cancer management: A multidisciplinary approach - medical, surgical & radiation oncology 
  Chapter: Chronic myelogenous leukemia 
  Page 797 - 810Cortes, J, Silver R, Kantarjian HCMP Healthcare Media2005
• Cancer management: A multidisciplinary approach - medical, surgical & radiation oncology 
  Chapter: Myelodysplastic syndromes 
  Page 825 - 842Cortes, J, List A, Kantarjian H2005
• Join now to see all

Abstracts/Posters

• Outcome of Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) without 3-Month Complete Molecular Response (CMR)
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best...
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Ultra-Accurate Assessment of Pretreatment ABL1 Kinase Domain (KD) Mutations in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic...
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS)
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Donor Clonal Hematopoiesis Increases Risk of Acute Graft Versus Host Disease after Matched Related Transplantation in AML and MDS Patients
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Efficacy Proof of Concept for Allogeneic CD123 Targeting CAR T-Cells Against Primary Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Efficient Control of Tumor P...
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Achievement of Complete Remission (CR) with Measurable Residual Disease (MRD) Negativity Is Highly Prognostic in Patients (pts) with Relapsed or Refractory (R/R) Acute...
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remis...
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase Ib/II Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly D...
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Phase II Trial of Azacitidine (AZA) in Combination with Ruxolitinib (RUX) in Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs)
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Determinants of Outcomes of FLT3mut Acute Myeloid Leukemia with First Salvage Therapy
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Updated Results from the Phase II Study of Hyper-CVAD in Sequential Combination with Blinatumomab in Newly Diagnosed Adults with B-Cell Acute Lymphoblastic Leukemia (B...
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Updated Preliminary Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Na¥ve (TN) AML Unfit for Intensive Chemothe...
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Multicenter Phase I Study Combining Venetoclax with Mini-Hyper-CVD in Older Adults with Untreated and Relapsed/Refractory Acute Lymphoblastic Leukemia
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Gene Expression Signature Predicts Deep Molecular Response (DMR) in Chronic Myeloid Leukemia (CML): An Exploratory Biomarker Analysis from ENESTnd
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Evolutionary Action (EA) Score of TP53 Mutations Defines Prognostic Subsets within TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Cell of Origin Classification of DLBCL Using Targeted NGS Expression Profiling and Deep Learning
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Effectiveness of Bosutinib in Chronic Myeloid Leukemia (CML) Who Have Received Multi Tyrosine Kinase Inhibitors (TKIs)
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Higher Stability of Mutant mRNA As Compared to Wild-Type mRNA in Diffuse Large B-Cell Lymphoma
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• The Early Achievement of Measurable Residual Disease Negativity in the Treatment of Adults with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia Is a Strong P...
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Characteristics and Outcomes of Therapy-Related Versus De Novo Acute Myeloid Leukemia with Normal Karyotype
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Medical Crossfire¬: Case Studies in AYA and Adult Acute Lymphoblastic Leukemia _ How the Experts Think and Treat 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Efficacy and Safety Outcomes in the Phase 3 INO-Vate Trial By Baseline CD22 Positivity Assessed By Local Laboratories 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Inotuzumab ozogamicin (InO) treatment in patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL): Outcomes of patients treated in salvage one with a l... 
  2019 ASCO Annual Meeting - 6/1/2019
• New approaches in acute lymphoblastic leukemia therapy 
  Cancun, Mexico - 1/28/2012
• Front line therapy for CML 
  Beirut, Lebanon - 1/21/2012
• Elderly AML: A continuous challenge 
  Beirut, Lebanon - 1/20/2012
• Treatment of high risk MDS 
  Beirut, Lebanon - 1/20/2012
• The Cure of Chronic Myelogenous Leukemia 
  San Diego, CA - 1/19/2012
• What is New in Acute Lymphoblastic Leukemia 
  San Diego, CA - 1/19/2012
• CML:Making a Choice Between Imatinib, Nilotinib and Dasatinib? Update on their Relative Advantages and Toxicities, Innovative Cancer Therapy for Tomorrrow 
  New York City, NY - 1/7/2012
• Lessons from CML: How Applying Targeted Therapy to Newly Diagnosed Disease Transformed Outcomes 
  Chicago, IL - 1/4/2012
• Drug Shortages: Why Is This Happening and How Can We Treat Our Patients? 
  Chicago, IL - 1/3/2012
• Update on the Satus of Drug Shortages, Causes, and Trends 
  Chicago, IL - 1/3/2012
• "Symposium AML". Developmental Therapeutics in AML, Leukemia and Lymphoma; East and West are Together 
  MD Anderson Cancer Center and Clinical Hospital Center Zagreb, Dubrovnik, Croatia - 1/17/2011
• "Symposium MDS". Developmental Therapeutics in MDS, Leukemia and Lymphoma; East and West are Together 
  MD Anderson Cancer Center and Clinical Hospital Center Zagreb, Dubrovnik, Croatia - 1/17/2011
• Imatinib-resistant chronic myeloid leukemia. Definitions and management 
  London, United Kingdom - 1/10/2011
• "Presidential Symposium" and Session: Chronic myeloid leukemia – therapy with TKI," and Speaker "AML – Risk adapted therapy II," East and West Together 
  Dubrovnik, Croatia - 1/15/2007
• Insights into the molecular biology of acute leukemia and the implications for treatment 
  San Diego, CA - 1/19/2005
• Is CML a curable malignancy without transplantation? 
  San Diego, CA - 1/19/2005
• What is new in AML, MDS and CML 
  Cleveland Cancer Center, Cleveland, OH - 1/16/2005
• Novel approaches in AML and MDS 
  Memorial Sloan Kettering Cancer Center, New York City, NY - 1/25/2004
• Update on AML and MDS 
  NYU Medical Center, New York City, NY - 1/25/2004
• CML State of the Art 
  Mt. Sinai Medical Center, New York City, NY - 1/24/2004
• Philadelphia chromosome positive ALL 
  Beirut, Lebanon - 1/19/2004
• Chronic myelogenous leukemia - what’'s new 
  The Winship Cancer Institute of Emory University - 1/17/2004
• Join now to see all

Other

• Patients Take Action Against Cancer Drug Prices 
  Kantarjian H, The Houston Chronicle
  1/1/2015
• High Cost of Cancer Drugs Goes Beyond the Price 
  Kantarjian H, Modern Healthcare
  http://www.modernhealthcare.com/article/20150404/MAGAZINE/304049978
  1/1/2015
• Expanding Medicaid under ACA Would Avert State Health Crisis 
  Kantarjian H, Ho V, The Houston Chronicle
  1/1/2015
• Insurers Play to Win, but the Patients Lose 
  Jain N, Kantarjian H, The Houston Chronicle Outlook Section
  1/1/2015
• Health Care in the U.S. Should be a Basic Human Right, not an Entitlement 
  Jones G, Kantarjian H, Baker Institute Blog
  1/1/2015
• What is the 340B Drug Discount Program and why is it so important? 
  Kantarjian H, Chapman R, James A. Baker Institute Blog, Insight and analysis from the James A. Baker III Institute for Public
  Rice University - 1/1/2015
• Medical Advances Continue to Help in Cancer Fight 
  Kantarjian H, Mendelsohn J, The Houston Chronicle
  1/1/2014
• State Policies and ACA Information Gap Hurt the Uninsured 
  Kantarjian, H, The Houston Chronicle
  1/1/2014
• New Trove of Medicare Cost Data an Eye-Opener 
  Kantarjian H, Ho V, The Houston Chronicle
  1/1/2014
• An Unhealthy System 
  Kantarjian, H, US News.com
  http://www.usnews.com/opinion/articles/2014/05/30/no-the-us-doesnt-have-the-best-health-care-system-in-the-world
  1/1/2014
• Cancer Rx: The $100,000 Myth 
  Light D, Kantarjian H, AARP
  1/1/2014
• Common Ground on Cutting Costs of Cancer 
  Kantarjian H, Newcomer L, Crenshaw N, The Hill.com
  http://thehill.com/blogs/congress-blog/healthcare/207631-common-ground-on-cutting-costs-of-cancer
  1/1/2014
• America's Health Care System Not as Perfect as We Think 
  Kantarjian, H, The Houston Chronicle
  1/1/2014
• Does the United States Have the Best Health-Care System in the World? 
  Kantarjian, H, The ASCO Post
  1/1/2014
• HPV vaccine should be Texas requirement 
  Matthews Kirstin RW, Kantarjian Hagop, The Houston Chronicle
  1/1/2014
• Relevance of the Hippocratic Oath in the 21st Century 
  Kantarjian H, Steensma D, The ASCO Post
  1/1/2014
• Deciphering the Hippocratic Oath in the 21st Century 
  Kantarjian H, James A. Baker Institute Blog, Insight and analysis from the James A. Baker III Institute for Public
  Rice University - 1/1/2014
• Texas and Medicaid 
  Kantarjian H, Ho V, James A. Baker Institute Blog, Insight and analysis from the James A. Baker III Institute for Public
  Rice University - 1/1/2014
• The Case for Universal Vaccination Against the Human Papillomavirus (HPV) 
  Kantarjian H, James A. Baker Institute Blog, Insight and analysis from the James A. Baker III Institute for Public
  Rice University - 1/1/2014
• Chemotherapy Drug Shortages in the U.S.-The Recurring Nightmare 
  Kantarjian H, Ho, V, James A. Baker Institute Blog, Insight and analysis from the James A. Baker III Institute for Public
  Rice University - 1/1/2014
• Parallels between the Affordable Care Act and the Civil Rights Act of 1964 
  Kantarjian H, James A. Baker Institute Blog, Insight and analysis from the James A. Baker III Institute for Public
  Rice University - 1/1/2014
• Health care news from Africa: Thumbs Up For Bush, down for pharma 
  Kantarjian, H, James A. Baker Institute Blog, Insight and analysis from the James A. Baker III Institute for Public
  Rice University - 1/1/2014
• The Promise of Cognitive Computing in Cancer Care 
  Kantarjian H, James A. Baker Institute Blog, Insight and analysis from the James A. Baker III Institute for Public
  Rice University - 1/1/2014
• It's time to price dugs by their value to patients 
  Kantarjian H, Zwelling L, The Houston Chronicle
  1/1/2013
• Making cancer drugs less expensive 
  Kantarjian H, Fojo T, Zwelling L, The Washington Post
  1/1/2013
• Join now to see all